Biomarkers of response to immune checkpoint blockade in cancer treatment

Area of Science:

• Oncology
• Immunology
• Biomarker Discovery

Background:

• Immune checkpoint inhibitors (ICPis) are a cornerstone of modern cancer therapy, offering durable responses in various malignancies.
• However, patient responses to ICPis are heterogeneous across cancer types, and treatment carries risks of immune-related adverse events.
• Effective patient selection is crucial due to treatment variability and potential toxicity.

Purpose of the Study:

• To review current immune monitoring strategies for patient selection in cancer immunotherapy.
• To highlight the challenges in developing predictive biomarkers for ICPi treatment response.
• To provide an overview of methods aiding appropriate patient stratification for ICPi therapy.

Main Methods:

• Literature review of immune monitoring techniques in cancer immunotherapy.
• Analysis of strategies for predicting response to immune checkpoint inhibitors.
• Discussion of biomarkers and immune cell dynamics within the tumor microenvironment.

Main Results:

• Current immune monitoring strategies aim to identify patients who will respond to ICPis.
• Predicting response remains challenging due to tumor microenvironment complexity and immune cell interactions.
• Various immune monitoring approaches are under investigation to improve patient selection.

Conclusions:

• Robust biomarkers are needed to predict patient response to immune checkpoint inhibitors.
• Immune monitoring strategies are essential for optimizing ICPi therapy and mitigating risks.
• Further research into immune monitoring will enhance personalized cancer treatment approaches.